Free Trial

Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Bullish market and investing concept with rising up digital green graphic arrow on dark technological background with forex market chart graphs and candlestick. 3D rendering — Photo

Key Points

  • Many analysts believe HIMS stock is due for a correction, but the stock continues to introduce new innovations that may lead to subscriber growth.
  • After a strong capital raise, Joby Aviation is ready to take flight.
  • Surging demand for gold and copper makes Hudbay Minerals a key mining stock to watch. 
  • Five stocks we like better than Hudbay Minerals.

To the disappointment of buy-and-hold investors, 2025 is shaping up to be a year where nimble traders are likely to see the biggest gains. That said, there’s nothing wrong with the steady performance offered by blue-chip stocks—a sound strategy for many investors.

For those with an appetite for growth and risk tolerance, several low-priced stocks are emerging as strong candidates to double in 2025. These stocks were among the biggest gainers in 2024 and are positioned in sectors expected to see significant action in the year ahead.

Continuous Innovation Can Send HIMS Stock Higher

Hims & Hers Health Today

Hims & Hers Health, Inc. stock logo
HIMSHIMS 90-day performance
Hims & Hers Health
$27.96 +0.02 (+0.07%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
52-Week Range
$8.14
$35.02
P/E Ratio
63.33
Price Target
$25.13
Hims & Hers Health Inc. NYSE: HIMS stock is up approximately 224% in the last 12 months, putting it on par with some of the top technology stocks. That makes many analysts believe the company will struggle as it faces tougher comparisons and competition from many companies, including Amazon.com Inc. NASDAQ: AMZN.

A specific concern is that GLP-1 drugs made up a significant portion of the company’s revenue in 2024. However, Hims & Hers may lose permission to sell its compounded version of GLP-1 drugs as shortages end at companies such as Eli Lilly & Co. NYSE: LLY.

Setting that aside, the company is embracing the future of healthcare by focusing on telehealth, licensed prescribers, and customized versions of popular medications. The company has shown it can do this in areas such as sexual health & performance and hair loss for men. And in 2025, the company plans to focus on the Hers side of the business with menopause treatments.

That bodes well for maintaining its subscriber base, which has grown at an annual rate above 60% in the last three years. Significant growth may be priced into the stock, but as long as the company continues to innovate, future growth may not be recognized.

Joby Aviation Is Well Capitalized But Can’t Afford Any Setbacks

Joby Aviation Today

Joby Aviation, Inc. stock logo
JOBYJOBY 90-day performance
Joby Aviation
$8.20 -0.17 (-1.97%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
52-Week Range
$4.50
$10.72
Price Target
$9.30
Joby Aviation Inc. NYSE: JOBY is one of the leading names in the emerging electronic vertical take-off and landing (eVTOL) vehicle markets. These flying taxis have moved well beyond the conceptual stage but are not yet commercially available.

The company expects that to change in 2025, pending FAA certification. The good news is that Joby advanced into the final stage of certification in December 2024. Not only that, but it raised over $700 million in capital in December, which includes $500 million from Toyota Motor Corp. NYSE: TM. This means that, even with a cash burn of around $100 million a month, it should have enough cash to get into production.

After doubling in 2024, JOBY stock is down over 7% in January 2025. Some of that is due to concerns about insider selling in the last month. While this can be concerning, many of these transactions are planned in advance and are done independently of the share price.

Joby can’t afford any meaningful setbacks, but if they continue to move towards commercialization, analysts are likely to raise their price targets above the current consensus price target of $9.30, which is a 12% increase from the price on January 16.

Hudbay Minerals May Glitter Along With Gold

Hudbay Minerals Today

Hudbay Minerals Inc. stock logo
HBMHBM 90-day performance
Hudbay Minerals
$8.56 -0.08 (-0.87%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
52-Week Range
$4.94
$10.49
Dividend Yield
0.12%
P/E Ratio
37.20
Price Target
$11.17
After pulling back to start the year, gold seems to have found a floor and continues to push higher. The surge in gold prices started to benefit mining stocks in 2024. Hudbay Minerals Inc. NYSE: HBM was one of the winners with the stock shooting up 60% in the last 12 months. Analysts have an $11.17 price target, which is a gain of nearly 30%.

That may be too low. The company recently marked a significant milestone by producing one million ounces of gold at its Lalor mine in Manitoba, Canada. With uncertainty surrounding budget deficits in the United States, gold is expected to have another strong year in 2025.

However, investing in Hudbay exposes investors to copper, silver, molybdenum, and zinc. In fact, the company specializes in copper production. The strong year for copper that analysts expected in 2024 never materialized. But that seems to be more a case of a delay. The base case for copper remains strong, with the need for data centers and the global shift to renewable energy, and copper is likely to be in strong demand. 

As of January 16, 2025, HBM stock has been trading around its 50-day moving average. Investors will want to watch the stock closely before it reports earnings in February. If the stock builds momentum, a doubling over the next twelve months may be in play.

Should You Invest $1,000 in Hudbay Minerals Right Now?

Before you consider Hudbay Minerals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hudbay Minerals wasn't on the list.

While Hudbay Minerals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report
Chris Markoch
About The Editor

Chris Markoch

Editor & Contributing Author

Retirement, Individual Investing

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Hims & Hers Health (HIMS)
3.3299 of 5 stars
$27.86-0.3%N/A63.50Hold$25.13
Amazon.com (AMZN)
4.7703 of 5 stars
$226.17+2.5%N/A48.44Moderate Buy$245.65
Eli Lilly and Company (LLY)
4.9959 of 5 stars
$731.71-3.4%0.71%79.08Moderate Buy$1,002.22
Joby Aviation (JOBY)
2.32 of 5 stars
$8.22-1.7%N/A-11.78Moderate Buy$9.30
Toyota Motor (TM)
3.4987 of 5 stars
$180.55-0.5%2.56%8.58HoldN/A
Hudbay Minerals (HBM)
4.4045 of 5 stars
$8.51-1.5%0.12%36.98Buy$11.17
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?
Affordable AI Stocks: 7 Picks Under $50

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines